z-logo
open-access-imgOpen Access
Benefit of Olaparib for BRCA-Mutated Advanced Ovarian Cancer
Author(s) -
Catlin Nalley
Publication year - 2020
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000723552.86174.ff
Subject(s) - olaparib , medicine , ovarian cancer , oncology , brca mutation , placebo , cancer , chemotherapy , parp inhibitor , progression free survival , pathology , alternative medicine , polymerase , poly adp ribose polymerase , gene , biochemistry , chemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom